The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
《每日生物技術脈搏》：布里斯托爾·邁爾斯、BridgeBio 簽署腫瘤學協議、FDA 點頭支持Lava Therapeutics血液癌研究等
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去24小時生物技術領域的熱門發展綜述：
Stocks In Focus
關注的股票
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio墨水公司與百時美施貴寶簽訂腫瘤SHP2抑制劑許可協定
BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398 in oncology.
BridgeBio製藥公司(納斯達克代碼：BBIO)日前宣佈與達成獨家許可協定。百時美施貴寶公司北京(紐約證券交易所代碼：BMY)開發腫瘤學領域的BBP-398並將其商業化。
BridgeBio will receive an upfront payment of $90 million, up to $815 million in milestone payments and tiered royalties in the low- to mid-teens.
BridgeBio將收到9000萬美元的預付款，其中高達8.15億美元的里程碑付款，以及中低檔青少年的分級特許權使用費。
BridgeBio will retain the option to acquire higher royalties in the U.S. in connection with funding a portion of development costs upon the...
BridgeBio將保留在美國獲得更高特許權使用...
登入免費觀看全文
登入/註冊